Back

Dyne Therapeutics stock drops 16% after Novartis DM1 trial setback

Verifying
  • Dyne Therapeutics stock fell after Novartis failed in a DM1 clinical trial.
  • 16% was the reported decline in Dyne Therapeutics’ stock.
  • The setback increased concerns about RNA-targeting therapies for muscle diseases.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.